Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

Endocrine-Related Cancer

Volumn 16, Issue 1, 2009, Pages 225-231

  Faggiano, A ^a   Grimaldi, F ^b   Pezzullo, L ^c   Chiofalo, M G ^c   Caraco C ^c   Mozillo, N ^c   Angeletti, G ^d   Santeusanio, F ^d   Lombardi, G ^a   Colao, A ^a   Avenia, N ^d   Ferolla, P ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CALCITONIN BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CELL PROLIFERATION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LYMPHADENECTOMY; MALE; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR CELL; BLOOD; CLINICAL TRIAL; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; POSTOPERATIVE COMPLICATION; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SCINTISCANNING; SECRETION; THYROID TUMOR; TUMOR RECURRENCE;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; CALCITONIN; CARCINOMA, MEDULLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 65549130102     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0152     Document Type: Article

References (32)

1. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH & Hor G 1998 a Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. European Journal of Nuclear Medicine 25 1277-1283.
2. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH & Hor G 1998b Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. European Journal of Nuclear Medicine 25 79-83.
3. Anthony LB, Martin W, Delbeke D & Sandler M 1996 Somatostatin receptor imaging: predictive and prognostic considerations. Digestion 57 50-53.
4. Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O & Ozguven MA 2001 Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clinical Nuclear Medicine 26 683-688.
5. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP & Parmentier C 1996 Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. Journal of Nuclear Medicine 37 912-916.
6. Berna L, Chico A, Matias-Guiu X, Mato E, Catafau A, Alonso C, Mora J, Mauricio D, Rodriguez-Espinosa J, Mari C et al. 1998 Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. European Journal of Nuclear Medicine 25 1482-1488.
7. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A et al. 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 86 5658-5671.
8. Celentano L, Sullo P, Klain M, Lupoli G, Cascone E & Salvatore M 1995 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma. Quarterly Journal of Nuclear Medicine 39 131-133.
9. Clarke SE 1988 Radionuclide imaging in thyroid cancer. Nuclear Medicine Communications 9 79-82.
10. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja PA, Lange H, Bredow J, Korber C & Grunwald F 2001 Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. European Journal of Nuclear Medicine 28 1671-1676.
11. de Groot JW, Links TP, Jager PL, Kahraman T & Plukker JT 2004 Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Annals of Surgical Oncology 11 786-794.
12. Guerra UP, Pizzocaro C, Terzi A, Giubbini R, Maira G, Pagliaini R & Bestagno M 1989 New tracers for the imaging of the medullary thyroid carcinoma. Nuclear Medicine Communications 10 285-295.
13. Hoefnagel CA, Delprat CC, Zanin D & van der Schoot JB 1988 New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clinical Nuclear Medicine 13 159-165.
14. Hoefnagel CA, Delprat CC & Valdes Olmos RA 1991 Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma. Journal of Nuclear Biology and Medicine 35 334-336.
15. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R,Monson JP, BesserGM, Foley R et al. 2001 Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 86 895-902.
16. Kebebew E, Ituarte PH, Siperstein AE, Duh QY & Clark OH 2000 Medullary thyroid cancer: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 1139-1148.
17. Khan N, Oriuchi N, Higuchi T & Endo K 2005 Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 12 254-260.
18. Kwekkeboom DJ & Krenning EP 1996 Somatostatin receptor scintigraphy in patients with carcinoid tumors. World Journal of Surgery 20 157-161.
19. Kwekkeboom DJ, Lamberts SW, Habbema JD & Krenning EP 1996 Cost-effectiveness analysis of somatostatin receptor scintigraphy. Journal of Nuclear Medicine 37 886-892.
20. Leboulleux S, Baudin E, Travagli JP & Schlumberger M 2004 Medullary thyroid cancer. Clinical Endocrinology 61 299-310.
21. Mucha SA, Kunert-Radek J & Pomorski L 2006 Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases. Endokrynologia Polska 57 452-455.
22. Musholt TJ, Musholt PB, Dehdashti F & Moley JF 1997 Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 122 1049-1060 (discussion 1060-1).
23. Ohta H, Yamamoto K, Endo K, Mori T, Hamanaka D, Shimazu A, Ikekubo K, Makimoto K, Iida Y & Konosha J 1984 A new imaging agent for medullary carcinoma of the thyroid. Journal of Nuclear Medicine 25 323-325.
24. Oishi S, Sasaki M, Sato T, Hirota Y & Takahashi M 1986 Imaging and uptake mechanism of 131I-meta-iodobenzylguanidine in medullary thyroid carcinoma. Endocrinologia Japonica 33 309-315.
25. Poston GJ, Thomas AM, Macdonald DW, Karvounaris D, Henderson BL, George P, Lynn JA & Lavender JP 1986 Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine. Nuclear Medicine Communications 7 215-221.
26. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC & Samaan NA 1984 Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 63 319-342.
27. Sasaki Y, Kubo A, Kusakabe K, Masaki H, Endo K, Yamashita M, Nakajo M & Kaneko M 1992 The assessment of clinical usefulness of 131I-MIBG scintigraphy for localization of tumors of sympathetic and adrenomedullary origin-a report of multicenter phase III clinical trials. Kaku Igaku 29 1083-1098.
28. Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG & McIlrath EM 1998 Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. Quarterly Journal of Medicine 91 295-301.
29. Shulkin BL & Shapiro B 1990 The role of imaging tests in the diagnosis of thyroid carcinoma. Endocrinology and Metabolism Clinics of North America 19 523-543.
30. Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Agoston P & Tron L 2002 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. Journal of Nuclear Medicine 43 66-71.
31. Troncone L, Rufini V, De Rosa G & Testa A 1989 Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma. Henry Ford Hospital Medical Journal 37 178-184.
32. Udelsman R, Mojiminiyi OA, Soper ND, Buley ID, Shepstone BJ & Dudley NE 1989 Medullary carcinoma of the thyroid: management of persistent hypercalcitonaemia utilizing [99mTc] (v) dimercaptosuccinic acid scintigraphy. British Journal of Surgery 76 1278-1281.